Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

RCT (n=95, Saudi Arabia) found combination of recombinant interferon beta-1b and lopinavir–ritonavir led to lower mortality than placebo among patients who had been hospitalised with laboratory-confirmed MERS (12 [28%] vs. 23 [44%] died by day 90; p=0.024).

Source:

New England Journal of Medicine